| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
NUMB controls p53 tumour suppressor activity.
|
Nature
|
2008
|
2.91
|
|
2
|
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
|
Genes Dev
|
2006
|
2.87
|
|
3
|
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.
|
Nature
|
2007
|
2.54
|
|
4
|
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
|
JAMA Oncol
|
2015
|
2.03
|
|
5
|
The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer.
|
Nat Cell Biol
|
2009
|
1.44
|
|
6
|
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.
|
J Clin Invest
|
2007
|
1.41
|
|
7
|
Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.
|
Cancer Res
|
2008
|
1.37
|
|
8
|
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes.
|
Genes Chromosomes Cancer
|
2005
|
1.17
|
|
9
|
An atlas of altered expression of deubiquitinating enzymes in human cancer.
|
PLoS One
|
2011
|
1.17
|
|
10
|
The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation.
|
EMBO Mol Med
|
2013
|
0.99
|
|
11
|
Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.
|
Neuroendocrinology
|
2011
|
0.96
|
|
12
|
Pirin inhibits cellular senescence in melanocytic cells.
|
Am J Pathol
|
2011
|
0.92
|
|
13
|
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.
|
Cancer Discov
|
2013
|
0.91
|
|
14
|
Lymphomas of the bone: a pathological and clinical study of 54 cases.
|
Int J Surg Pathol
|
2002
|
0.91
|
|
15
|
CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
|
Virchows Arch
|
2003
|
0.90
|
|
16
|
Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system.
|
J Clin Pathol
|
2012
|
0.87
|
|
17
|
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
|
Pigment Cell Melanoma Res
|
2011
|
0.87
|
|
18
|
Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity.
|
J Exp Med
|
2008
|
0.86
|
|
19
|
Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
|
Cell Oncol (Dordr)
|
2014
|
0.81
|
|
20
|
DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer.
|
Am J Clin Oncol
|
2010
|
0.80
|
|
21
|
Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
|
Regul Pept
|
2013
|
0.79
|
|
22
|
ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity.
|
Sci Rep
|
2015
|
0.75
|
|
23
|
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
|
Adv Anat Pathol
|
2017
|
0.75
|
|
24
|
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
|
Adv Anat Pathol
|
2017
|
0.75
|